Illustration: Assistant editor Kathy Wong for Endpoints News
Investors have pulled back from the biotech industry in recent months. But not Pablo Legorreta, who quietly pioneered a drug development niche that’s in demand.
Legorreta is the CEO and founder of Royalty Pharma, which is among a handful of specialty firms that buy future royalties for drugs that are approved or in late-stage clinical trials. In exchange, patent holders often get cash upfront, but in an amount that’s less than what they would otherwise receive over a royalty’s lifespan.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.
